Head-To-Head Survey: ClearPoint Neuro (NASDAQ:CLPT) vs. Baird Medical Investment (NASDAQ:BDMD)

ClearPoint Neuro (NASDAQ:CLPT) and Baird Medical Investment (NASDAQ:BDMD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.

Earnings and Valuation

This table compares ClearPoint Neuro and Baird Medical Investment”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$40.61 million	13.82	-$25.54 million	($1.01)	-18.53
Baird Medical Investment	$22.54 million	2.15	N/A	N/A	N/A

Baird Medical Investment has lower revenue, but higher earnings than ClearPoint Neuro.

Profitability

This table compares ClearPoint Neuro and Baird Medical Investment’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-71.57%	-140.96%	-36.98%
Baird Medical Investment	N/A	N/A	N/A

Institutional and Insider Ownership

30.1% of ClearPoint Neuro shares are held by institutional investors. Comparatively, 19.8% of Baird Medical Investment shares are held by institutional investors. 6.9% of ClearPoint Neuro shares are held by insiders. Comparatively, 78.9% of Baird Medical Investment shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

ClearPoint Neuro has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Baird Medical Investment has a beta of -1.17, meaning that its stock price is 217% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for ClearPoint Neuro and Baird Medical Investment, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1	0	2	0	2.33
Baird Medical Investment	1	0	0	0	1.00

ClearPoint Neuro presently has a consensus target price of $23.00, indicating a potential upside of 22.86%. Given ClearPoint Neuro’s stronger consensus rating and higher probable upside, research analysts plainly believe ClearPoint Neuro is more favorable than Baird Medical Investment.

Summary

ClearPoint Neuro beats Baird Medical Investment on 7 of the 11 factors compared between the two stocks.

About ClearPoint Neuro

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

About Baird Medical Investment

Baird Medical Investment Holdings Ltd. is a medical technology company, which engages in the development and provision of medical devices. It is also involved in the design, development, manufacturing, and sale of microwave ablation medical devices, as well as sale of other medical devices. The company was founded on June 16, 2023 and is headquartered in Guangzhou, China.